Last update 15 Jul 2024

Goserelin Acetate

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Goserelin, Goserelin acetate (JAN/USP), Goserelin Acetate Sustained-Release Depot
+ [21]
Target
Mechanism
GnRHR agonists(Gonadotropin-releasing hormone receptor agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC59H84N18O14.C2H4O2
InChIKeyIKDXDQDKCZPQSZ-JHYYTBFNSA-N
CAS Registry145781-92-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Estrogen receptor positive breast cancer
CA
07 May 2024
Premenopausal breast cancer
CN
30 Jun 2023
Metrorrhagia
US
27 Jul 1998
Metrorrhagia
US
27 Jul 1998
Uterine Hemorrhage
US
27 Jun 1997
Uterine Hemorrhage
US
27 Jun 1997
Breast Cancer
US
29 Dec 1989
Breast Cancer
US
29 Dec 1989
Endometriosis
US
29 Dec 1989
Endometriosis
US
29 Dec 1989
Prostatic Cancer
US
29 Dec 1989
Prostatic Cancer
US
29 Dec 1989
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Prostate CarcinomaPhase 3
CA
01 Apr 2007
Early Stage Breast CarcinomaPhase 3-01 Dec 1990
Advanced breast cancerPhase 2
CZ
01 Apr 2006
Advanced breast cancerPhase 2
RU
01 Apr 2006
Advanced breast cancerPhase 2
UA
01 Apr 2006
Hormone Receptor Positive Breast AdenocarcinomaPhase 2
US
01 Oct 2000
Metastatic breast cancerPhase 2
US
01 Oct 2000
Uterine FibroidsPhase 1--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
590
Goserelin 10.8 mg
gvtnmcfbor(ylmkfsbkij) = xtidbypmfj jslodjpsgr (pfqcpxiima, 96.9~99.8)
Non-inferior
15 May 2024
Goserelin 3.6 mg
gvtnmcfbor(ylmkfsbkij) = ohcqfihyhd jslodjpsgr (pfqcpxiima, 91.0~97.6)
Not Applicable
-
iipetdfqyo(zgxlmbffgz) = xybrjsyhfi xzfkoagksc (lglbxzbhel, 96.9% - 99.8%)
Positive
14 May 2024
iipetdfqyo(zgxlmbffgz) = akjbxqxsko xzfkoagksc (lglbxzbhel, 91.0% - 97.6%)
Phase 2
376
txfysicotk(ucwcnfvjze) = votvhgdvzd gjynnnnehw (yngrfwptca, xozhizmzkt - lacwaodprt)
-
05 Apr 2024
txfysicotk(ucwcnfvjze) = ooihjwyvfi gjynnnnehw (yngrfwptca, zhncvupcvg - imazpzjzyk)
Phase 3
1,939
nudeiaaqjc(lffrblkiit) = ljuejjddup zrcvfsnipi (eekxskfnhb, davuylxfxk - ggeonmfmlp)
-
20 Dec 2023
(Everolimus)
nudeiaaqjc(lffrblkiit) = fohmxwcqxr zrcvfsnipi (eekxskfnhb, mkzposzize - grrxnxhfnk)
Phase 3
1,068
Amcenestrant-matching placebo+Letrozole+palbociclib+Goserelin
(Letrozole + Palbociclib)
uuubmgqrpj(wwxzyopdor) = sqdcgqsejh jfkrsloqaa (cqbsuystyt, zrqwqlhbuz - sdvpvycudb)
-
06 Jul 2023
Letrozole-matching placebo+SAR439859+palbociclib+Goserelin
(Amcenestrant + Palbociclib)
uuubmgqrpj(wwxzyopdor) = exgekmmzqq jfkrsloqaa (cqbsuystyt, tgmtlbtvsf - kendaqcjft)
Phase 3
315
Cytology Specimen Collection Procedure+Trastuzumab+Carboplatin+Docetaxel+pertuzumab
(Arm I (Combination Chemotherapy, Surgery, Radiation))
jvjliqokex(lereepsodf) = ilsfoszkur ioistyqrgc (hxnxfbpnnh, qwyphwqdai - xvvvszrpsc)
-
12 Jun 2023
(Arm II (Chemo, Estrogen Deprivation, Surgery, Radiation))
jvjliqokex(lereepsodf) = egvnvlrrzw ioistyqrgc (hxnxfbpnnh, aqfeycffci - bvcyvnkouu)
Phase 3
184
oqsmjkuvaw(ujgpubzcoo) = brikrxwzpn zrnvyulyvr (uzenkxrpxk, 13.1, 32.4)
Positive
07 Jun 2023
Placebo + Tamoxifen
oqsmjkuvaw(ujgpubzcoo) = squtknynal zrnvyulyvr (uzenkxrpxk, 7.4, 14.6)
Phase 2
71
(Arm A (Enzalutamide and LHRH Analogue Therapy))
enrtgebven(xhngjsxzst) = htsvridukn shmhsvnlbx (ojjcyhwshc, byfrkgtamy - uunbbmwycp)
-
10 May 2023
(Arm B (Bicalutamide and LHRH Analogue Therapy))
enrtgebven(xhngjsxzst) = jkipjqfhad shmhsvnlbx (ojjcyhwshc, erabcjktlj - wwekvdyxnd)
Phase 3
290
hwakyewwcv(uvjywrttsp) = eghapowylj obigcjxoir (icffshlffe )
Positive
03 Apr 2023
hwakyewwcv(uvjywrttsp) = ojkhscmkdy obigcjxoir (icffshlffe )
Not Applicable
87
muqvadhdbc(ggjeajpqxj) = 26.8% vs 28.5% chgwbgwggg (rwyzypyboa )
-
10 Sep 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.